Executive Vice President Donghyun Kim of RudaCure presented the efficacy of the drug RCI001 currently under development at the European Dry Eye Society annual conference held in Krakow, Poland, which aims to address the unmet needs of dry eye disease patients in Europe. This year's event was held from June 19th to 21st.
The conference is held annually and served as an opportunity to demonstrate the excellence of RCI001 to many European dry eye researchers.
Additionally, during the 2025 BIO-USA period, RudaCure shared the RCI001 development progress with Thea of France and Santen of Japan, and discussed future development issues.